Latash Investments’s AnaptysBio ANAB Stock Holding History

Latash Investments’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Hold	4,393	–	–	0.22%	17
2026 Q1	$244K	Hold	4,393	–	–	0.19%	18
2025 Q4	$213K	Buy	+4,393	New	+$171K	0.14%	17

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Latash Investments's ANAB Position: Q2 2026 in Review

Latash Investments held its AnaptysBio (ANAB) position steady in Q2 2026 at 4,393 shares worth $297K. The position accounts for 0.22% of the portfolio, ranked #17.

Latash Investments first reported a position in ANAB in Q4 2025 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Latash Investments held 4,393 shares of AnaptysBio worth $297K as of Q2 2026.
Latash Investments left its AnaptysBio share count unchanged in Q2 2026.
AnaptysBio made up 0.22% of Latash Investments's portfolio in Q2 2026, its #17 holding.
Latash Investments first reported a position in AnaptysBio in Q4 2025 and has held it in 3 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Latash Investments's 13F filing for Q2 2026, filed 11 Aug 2026.